Genzyme Corporation

Genzyme Corporation, often referred to simply as Genzyme, is an American biotechnology company founded in 1981 in Boston, Massachusetts. Since 2011, it has operated as a wholly-owned subsidiary of the French multinational pharmaceutical company Sanofi, which acquired Genzyme for approximately $20.1 billion. Genzyme's headquarters are in Cambridge, Massachusetts. Prior to its acquisition, in 2010, Genzyme was the world's third-largest biotechnology company, employing over 11,000 people globally and reporting revenue of $4 billion. As a Sanofi business unit, Sanofi Genzyme has approximately 10,000-12,000 employees and generates an estimated $4.6 billion in annual revenue.

Genzyme focuses on developing and delivering transformative therapies, particularly for rare genetic disorders, multiple sclerosis, immunology, and oncology. Key product areas include treatments for lysosomal storage diseases like Gaucher disease (Cerezyme) and Fabry's disease (Fabrazyme), as well as products for renal disease, orthopedics, transplant and immune diseases, and diagnostic testing. The company has a significant presence in global markets, with products sold in approximately 90 countries.

Genzyme Corporation is an active participant in patent litigation, having appeared as a plaintiff in one tracked case and as a defendant in one tracked case. This indicates a posture of both asserting its intellectual property and defending against challenges. Both tracked cases involve disputes with Novartis Gene Therapies, Inc., taking place in the District Court for the District of Delaware and the Patent Trial and Appeal Board, common venues for patent disputes.

One notable case is Genzyme Corporation v. Novartis Gene Therapies, Inc., filed in the District Court for the District of Delaware in 2021. In this suit, Genzyme Corporation and Aventis Inc. (also a Sanofi subsidiary) asserted six patents covering recombinant adeno-associated virus (AAV) vector technology, directly targeting Novartis's gene therapy drug, Zolgensma, which treats spinal muscular atrophy. This high-stakes litigation, which lasted 796 days, concluded in February 2024 with a dismissal with prejudice, meaning Genzyme cannot refile the same patent claims against Novartis. The other tracked case, Novartis Gene Therapies, Inc. et al. v. Genzyme Corporation, involves proceedings before the Patent Trial and Appeal Board, likely related to the same AAV vector technology.Genzyme Corporation, commonly known as Genzyme, is an American biotechnology company founded in Boston, Massachusetts, in 1981. Since its acquisition in 2011 for approximately $20.1 billion, Genzyme has operated as a wholly-owned subsidiary of the French multinational pharmaceutical company Sanofi. The company maintains its headquarters in Cambridge, Massachusetts. Before becoming a Sanofi subsidiary, Genzyme was the world's third-largest biotechnology firm in 2010, employing over 11,000 people and generating $4 billion in revenue. Currently, as a global business unit of Sanofi, Genzyme has an estimated workforce of 10,000 to 12,000 employees and annual revenues around $4.6 billion.

Genzyme focuses on the development and delivery of therapies for rare genetic disorders, multiple sclerosis, immunology, and oncology. Its product portfolio includes treatments for lysosomal storage diseases such as Cerezyme for Gaucher disease and Fabrazyme for Fabry's disease, alongside offerings for renal disease, orthopedics, transplant and immune diseases, and diagnostic testing. The company's products are distributed in approximately 90 countries worldwide.

Genzyme Corporation maintains an active patent litigation posture, appearing both as a plaintiff and a defendant in its two tracked cases. This indicates its engagement in both enforcing its intellectual property and defending against infringement allegations. The cases are situated in the District Court for the District of Delaware and before the Patent Trial and Appeal Board, which are common forums for patent disputes.

A prominent case is Genzyme Corporation v. Novartis Gene Therapies, Inc., filed in the District Court for the District of Delaware in December 2021. In this suit, Genzyme Corporation, along with co-plaintiff Aventis Inc., accused Novartis Gene Therapies, Inc., of infringing six patents related to recombinant adeno-associated virus (AAV) vector technology, specifically targeting Novartis's gene therapy drug, Zolgensma, for spinal muscular atrophy. The litigation concluded in February 2024 with a dismissal with prejudice, preventing Genzyme from refiling the same patent claims against Novartis. The other tracked case, Novartis Gene Therapies, Inc. et al. v. Genzyme Corporation, involves proceedings at the Patent Trial and Appeal Board, likely pertaining to related AAV vector technologies.